Effects of oral propafenone therapy on chronic myocardial pacing threshold.
The effects of oral propafenone therapy on pacing threshold were studied in 36 patients chronically paced for sick sinus syndrome or AV block. The pacemakers, all unipolar models and with noninvasive threshold measurement facilities, were: 9 VVI, 15 AAI, and 12 DDD. Each patient received an initial propafenone dose of 450 mg/day, that in 18 cases was increased to 900 mg/day. Threshold was tested at baseline and at each dosage after 7 days of therapy. With the lower propafenone dosage the threshold, measured at 2.5 V, rose from 0.14 +/- 0.10 to 0.21 +/- 0.16 msec (+55%) in the atrium (P less than 0.0001) and from 0.10 +/- 0.08 to 0.15 +/- 0.09 msec (+63%) in the ventricle (P less than 0.0001). In the 18 patients who received both dosages, the mean atrial and ventricular threshold increased from 0.12 +/- 0.10 to 0.17 +/- 0.14 msec with the lower dose and to 0.27 +/- 0.22 msec (+125%) with the higher dose (P less than 0.0001 for both increments). With the 900 mg/day dose, a threshold increment greater than or equal to 300% was observed in 15% of the stimulated chambers. A good linear correlation (r = 0.76) was found between the ventricular threshold increment and the drug induced QRS widening. In conclusion, treatment with oral propafenone increases atrial and ventricular stimulation threshold in pacemaker patients. Threshold increment is dose dependent and proportional to the drug induced QRS widening. In the majority of the cases the threshold increment is not clinically significant, but caution must be used in prescribing high doses of the drug to patients with high baseline threshold.
Bianconi
L
L
Division of Cardiology, San Filippo Neri Hospital, Rome, Italy.
Boccadamo
R
R
Toscano
S
S
Serdoz
R
R
Carpino
A
A
Iesi
A P
AP
Altamura
G
G
D000368:Aged; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D005260:Female; D006327:Heart Block / Q000628:therapy*; D006329:Heart Conduction System / Q000187:drug effects; D006801:Humans; D008297:Male; D010138:Pacemaker, Artificial; D011405:Propafenone / Q000008:administration & dosage* / Q000627:therapeutic use; D012804:Sick Sinus Syndrome / Q000628:therapy*
D011405:Propafenone